Chairman of the Board of Directors of Karolinska Development resigns at his own request

STOCKHOLM, SWEDEN – December 11, 2024. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that the company’s Chairman of the Board of Directors, Professor Hans Wigzell, has decided to resign from his position. The Board of Directors will immediately begin a process to appoint a new President.

Hans Wigzell has played an instrumental role in Karolinska Development since the company was founded. He has served as Chairman of the Board for several periods, most recently since the 2024 Annual General Meeting.

For more information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Telephone: +46 73 982 52 02, e-mail: [email protected]

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Telephone: +46 70 207 48 26, e-mail: [email protected]

This information is information that Karolinska Development is required to make public in accordance with the European Market Abuse Regulation. The information was submitted for publication, via the contact persons indicated above, on 11/12/2024 at 11:45 CET.

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region, developed by entrepreneurs and management teams. The Company invests in building and growing businesses that translate these assets into commercial products designed to make a difference in the lives of patients while providing an attractive return on investment for shareholders.

Karolinska Development has access to world-class medical innovations at Karolinska Institutet and other leading universities and research institutes in the Nordic region. The company aims to build businesses around leading scientists in their field, supported by experienced management teams and advisors, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of eleven companies targeting opportunities in the field of innovative treatments for life-threatening or serious debilitating diseases.

The company is led by an entrepreneurial team of investment professionals with a proven track record as business builders and access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

KD Ordfo¨rande 2024-12-11 ENG